Business
Therma Bright Sells an Additional 200-Units of Venowave(TM) to Strategic Distribution Partner Gen-X Med
Toronto, Ontario--(Newsfile Corp. - January 20, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce it has received a follow-on order for an additional 200 Venowave™ VW5 units from its Texas-based distribution partner, Gen-X Med. This latest transaction marks the expansion of the relationship between the two companies,..
About this update from Gentherm Inc
[{"type":"text","content":"Toronto, Ontario--(Newsfile Corp. - January 20, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce it has received a follow-on order for an additional 200 Venowave™ VW5 units from its Texas-based distribution partner, Gen-X Med.","length":427,"tagName":"p"},{"type":"text","content":"This latest transaction marks the expansion of the relationship between the two companies, following the successful initial integration of the Venowave™ system into Gen-X Med's specialized healthcare network. The units are destined for use by top-tier orthopedic surgeons, specifically targeting post-surgical recovery for specialized knee procedures-a high-growth segment in the U.S. healthcare landscape.","length":410,"tagName":"p"},{"type":"text","content":"Rob Fia, CEO, commented:"The speed at which Gen-X Med has returned for additional inventory speaks volumes about the clinical demand for the Venowave™ VW5. This second 200-unit order reinforces our belief that the market is hungry for mobile, effective, and reimbursable compression solutions. By helping surgeons reduce post-operative complications and hospital readmissions, we are not only improving patient lives but also providing a clear economic benefit to the U.S. healthcare system. We look forward to scaling this volume as Gen-X Med continues to educate their expansive doctor network."","length":608,"tagName":"p"},{"type":"text","content":"Beau Wood, President of Gen-X Med, commented: "Our initial rollout confirmed what we suspected: patients and providers prefer the mobility and efficacy of the Venowave™ over traditional, tethered compression devices. Securing these additional 200 units allows us to keep pace with the growing adoption rate among our specialized knee surgeons. We are seeing a shift toward 'at-home' recovery solutions, and Venowave™ is the clear leader in that transition."","length":476,"tagName":"p"},{"type":"text","content":"The Growing Compression Therapy MarketThe global compression therapy market is currently experiencing significant tailwinds. According to industry data from Straits Research, the market was valued at **$4.18 billion in 2024 and...